These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 32295593

  • 1. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
    Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, Tillmann HC.
    Respir Res; 2020 Apr 15; 21(1):87. PubMed ID: 32295593
    [Abstract] [Full Text] [Related]

  • 2. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct 15; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
    Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, Pfister P.
    Respir Med; 2020 Oct 15; 170():106021. PubMed ID: 32843164
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
    Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC.
    Adv Ther; 2022 Jun 15; 39(6):2365-2378. PubMed ID: 35072888
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Patalano F, Banerji D.
    COPD; 2016 Dec 15; 13(6):686-692. PubMed ID: 27715335
    [Abstract] [Full Text] [Related]

  • 9. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
    Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 15; 13():3923-3936. PubMed ID: 30584293
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV, FLASH Investigators.
    Respirology; 2018 Dec 15; 23(12):1152-1159. PubMed ID: 30074294
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S, Jauernig J, Ethell B, Abdallah N, Machineni S, Drollmann A, Heudi O, Last S, Hahn M, Radhakrishnan R, Ignatenko S, Tillmann HC.
    Pulm Pharmacol Ther; 2020 Oct 15; 64():101964. PubMed ID: 33035700
    [Abstract] [Full Text] [Related]

  • 12. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
    Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct 15; 11():3189-3197. PubMed ID: 28008244
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma.
    Buhl R, Nikolaev I, Tillmann HC, Vaidya S, Bartels C, Jain M, Jauernig J, Kerstjens HAM.
    Pulm Pharmacol Ther; 2021 Oct 15; 70():102068. PubMed ID: 34329722
    [Abstract] [Full Text] [Related]

  • 15. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma.
    Bartels C, Jain M, Yu J, Tillmann HC, Vaidya S.
    Eur J Drug Metab Pharmacokinet; 2021 Jul 15; 46(4):487-504. PubMed ID: 34024035
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O, Mucsi J, Kolosa N, Bandelli L, Sen B, Satlin LC, D'Andrea P.
    Respir Med; 2020 Jan 15; 161():105809. PubMed ID: 32056721
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
    Sagara H, Barbier N, Ishii T, Yoshisue H, Nikolaev I, Hosoe M, Gon Y.
    BMJ Open Respir Res; 2021 Mar 15; 8(1):. PubMed ID: 33737310
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
    van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P.
    J Asthma Allergy; 2023 Mar 15; 16():123-134. PubMed ID: 36714049
    [Abstract] [Full Text] [Related]

  • 20. Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studies.
    Gon Y, Ishii T, Lawrence D, Nikolaev I, Wang D, Sumi K, Nakamura Y.
    J Asthma; 2022 Aug 15; 59(8):1627-1637. PubMed ID: 34346266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.